Oral vaccines are superior to current vaccine technology, with advantages in terms of physical distribution, storage and administration as well as the immune response they provoke.
The OraPro oral vaccine platform delivers prolonged thermal stability at ambient temperature, eliminating the cold chain, and even the ultra cold chain, from vaccine distribution.
The drawbacks of injection-based vaccines 
of world’s population cannot obtain vaccines due to vaccine storage temperatures requirements
OraPro Approach The OraPro thermal stability platform completely removes the need for refrigeration for storage, thus enabling vaccines to be shipped, stored and delivered at room temperatures, overcoming the logistical and economic challenges of global distribution.
The drawbacks of injection-based vaccines 
of vaccines are wasted due to temperature excursions and logistics
OraPro Approach Because no refrigeration is required to transport OraPro capsules, the distribution process is significantly simpler and cheaper and eliminates potential temperature excursion wastage.
The drawbacks of injection-based vaccines 
of total injection cost is the cost of administration by the healthcare professional
OraPro Approach Oral vaccinations do not require administration by a healthcare professional; a tablet can be provided directly to the patient to take at home. This will significantly reduce costs and improve the ease with which vaccines can be delivered to patients in the developing world.
The drawbacks of injection-based vaccines 
of adult patients avoid flu shots due to needle fear or phobias
OraPro Approach When given an option, 98.7% people preferred oral self-administered vaccine. Thus, OraPro platform will likely enable greater vaccine adoption among populations.
Follow us
Enabling the fastest and most cost-effective deployment of vaccines the world has ever seen. This is not just a huge leap forward from a humanitarian perspective, oral vaccine technology also represents a significant commercial opportunity.
As the coronavirus pandemic rages on around the world, scientists are working day and night to create safe and effective vaccines that will allow life to return to normal. Although great leaps forward have been made, we are already seeing the supply chain and logistical problems of injectable vaccines that require cold or ultra cold chain storage. And as further mutations of the virus continue to emerge, the ability to tweak and readminister vaccines becomes ever more crucial.
iosBio has partnered with US pharmaceutical company ImmunityBio to create OraPro-Covid-19, deploying our ground-breaking oral vaccine delivery platform with the aim of creating a Covid-19 vaccine that can be sent by post and swallowed at home.
closeThe global seasonal influenza market is forecast to be worth $4.3bn by 2025. This figure is unsurprising considering the enormous economic costs of flu each year.
On average, the total estimated annual economic burden of influenza to the US healthcare system and society is $11.2 billion, comprising $3.2 billion in direct medical costs and $8 billion in indirect costs. The CDC (Centre for Disease Control and Prevention) recommends that every person from the age of six months onwards has a flu vaccine, but actual vaccination coverage hovers around 50%
In the UK, six million working days are lost to seasonal influenza in an average winter, yet uptake amongst the under-65s has been steadily declining in recent years. Many cite difficulties with getting an appointment at their GP’s surgery, where the vast majority of flu jabs are still administered.
closeZika virus disease is caused by a virus transmitted primarily by mosquitoes, as well as through sexual contact and from mother to fetus during pregnancy. Zika infection during pregnancy can cause infants to be born with microcephaly and other congenital malformations, and is also associated with other complications including preterm birth and miscarriage. An increased risk of neurologic complications is associated with Zika virus infection in adults and children, including Guillain-Barré syndrome, neuropathy and myelitis.
From the 1960s to 1980s, rare sporadic cases of human infections were found across Africa and Asia, typically accompanied by mild illness. The first recorded outbreak of Zika virus disease was reported from the Island of Yap in Micronesia in 2007. This was followed by a large outbreak of Zika virus infection in French Polynesia in 2013 and other countries and territories in the Pacific. In March 2015, Brazil reported a large outbreak of rash illness, soon identified as Zika virus infection, and later that year confirmed to be associated with microcephaly and Guillain-Barré syndrome.
close